AbbVie Inc.$245.80LLY · NYSE
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B | $24.54B | $22.32B | $21.49B |
| Cost of Revenue | $11.05B | $8.42B | $7.08B | $6.63B | $7.31B | $5.48B | $4.72B | $4.68B |
| Research & Development | — | — | — | $7.19B | $6.93B | $5.98B | $5.59B | $5.05B |
| Selling, General & Administrative | $11.09B | $8.59B | $7.40B | $6.44B | $6.43B | $6.12B | $6.21B | $5.98B |
| Interest Expense | — | — | $485.90M | $331.60M | $339.80M | $359.60M | $400.60M | $242.50M |
| Other Income / (Expense) | -$571.00M | -$219.00M | $97.00M | -$320.90M | -$201.60M | $1.17B | $291.60M | $145.60M |
| Income Before Taxes | $25.73B | $12.68B | $6.55B | $6.81B | $6.16B | $7.23B | $5.27B | $3.68B |
| Provision for Income Taxes | $5.09B | $2.09B | $1.31B | $561.60M | $573.80M | $1.04B | $628.00M | $529.50M |
| Net Income | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B | $6.19B | $8.32B | $3.23B |
| Basic EPS | $23.00 | $11.76 | $5.82 | $6.93 | $6.15 | $6.82 | $8.93 | $3.14 |
| Diluted EPS | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 | $6.79 | $8.89 | $3.13 |
| Basic Shares Outstanding | 897.30M | 900.60M | 900.20M | 901.74M | 906.96M | 907.63M | 931.06M | 1.03B |
| Diluted Shares Outstanding | 899.30M | 904.10M | 903.30M | 904.62M | 911.68M | 912.50M | 935.68M | 1.03B |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | $34.71 | $32.53 | $37.20 | 7 | ↑0 ↓7 |
| Dec 2027 | $44.98 | $40.40 | $47.27 | 9 | ↑6 ↓1 |
| Dec 2028 | $54.27 | $48.66 | $57.92 | 3 | ↑2 ↓0 |
| Dec 2029 | $54.25 | $54.25 | $54.25 | 1 | ↑0 ↓0 |
